Key result
Spinal cord stimulation improves symptoms and reduces nitroglycerin use in refractory angina.
Why the study?
Spinal cord stimulation is increasingly explored beyond established neuropathic pain indications, prompting a synthesis of clinical studies in refractory visceral pain, autonomic dysfunction, and cardiovascular conditions.
Does implanted spinal cord stimulation improve symptom control, pain, and functional outcomes in patients with refractory visceral pain, autonomic dysfunction, and cardiovascular conditions such as refractory angina?
Does implanted spinal cord stimulation improve symptom control, pain, and functional outcomes in patients with refractory visceral pain, autonomic dysfunction, and cardiovascular conditions such as refractory angina?
This narrative review highlights that spinal cord stimulation has a well-developed evidence base for improving symptoms and quality of life in refractory angina, while evidence for emerging visceral pain, autonomic, and peripheral ischemic indications remains preliminary and requires large randomized trials.
Answers are grounded in this paper and cite their sources.
May support SCS consideration in refractory angina; leaves open its role in other visceral and ischemic conditions pending RCTs.
Spinal cord stimulation (SCS) is increasingly being explored beyond established neuropathic pain indications, including in visceral pain, autonomic dysfunction, and cardiovascular conditions. We conducted a structured narrative review of English-language clinical studies published between 2000 and 2025 investigating SCS for visceral pain or autonomic dysfunction. A structured search limited to PubMed identified 112 articles, and reference-list review identified 16 more; of these, 31 studies met inclusion criteria after screening. Refractory angina had the strongest evidence base. Multiple trials showed improved symptom control and reduced nitroglycerin use. Additionally, historical data from a single randomized cohort of selected high-risk patients showed similar improvements in angina symptoms and quality of life, along with similar 5-year mortality after SCS and coronary artery bypass grafting. Smaller, mostly uncontrolled studies of chronic abdominal, pancreatic, and pelvic pain reported at least 50% pain reduction in most patients. However, the only sham-controlled trial, conducted in chronic pancreatitis, found no benefit during blinded stimulation. Functional improvements in neurogenic bowel were observed, but the evidence was limited by small sample sizes and the absence of controls. Studies of cardiac syndrome X and critical limb ischemia also reported symptomatic benefit, but large-scale validation is lacking. Overall, SCS shows potential clinical benefit in refractory visceral pain and cardiovascular conditions, particularly refractory angina. However, the evidence outside angina remains limited and heterogeneous. Large, multicenter randomized trials using standardized outcomes are needed to clarify long-term efficacy and better define the role of SCS in these emerging indications.
No takes yet. Share an insight, caveat, or question.
Sandhu et al. (2026) conducted a review in Refractory visceral pain, autonomic dysfunction, and cardiovascular conditions (including refractory angina pectoris, cardiac syndrome X, and critical limb ischemia). Spinal cord stimulation (SCS) vs. Sham stimulation, subthreshold stimulation, coronary artery bypass grafting, percutaneous myocardial laser revascularization, medical management, or no control (across included studies) was evaluated on Symptom control, pain scores, functional status, quality of life, and medication use across reviewed indications. Spinal cord stimulation improved symptom control and reduced nitroglycerin use across 11 refractory angina studies, while evidence in other visceral and ischemic conditions remained limited.
Synapse has enriched 10 related papers. Consider them for comparative context: